Meropenem
FDA-approved product (injectable, injection), marketed as Meropenem, Meropenem And Sodium Chloride In Duplex Container, Merrem Iv.
- Registered studies
- 50+
- Lab records
- 263
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Bacterial meningitis
- Bacteriemia
- Infection
- Infectious meningitis
- Meningitis
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Carbapenems
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01DH02
Repurposing investigation
Meropenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA96.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli99.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 16 of 17 lab records
- E. coli: measured active in 38 of 38 lab records
- K. pneumoniae: measured active in 172 of 208 lab records
Show the latest 150 of 263 laboratory records, with sources
Loading records…
Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Meropenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)
NCT03120663 · start 2016-11-30
Registered record
- Registry ID
- NCT03120663
- Conditions
- Surgery
- Interventions
- amoxicillin-clavulanic acid
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2016-11-30
- Completion
- 2018-09-30
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSurgeryInterventionamoxicillin-clavulanic acidPhaseNot recordedRegistry statusUnknownEfficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections
NCT02784704 · start 2016-10-13
Registered record
- Registry ID
- NCT02784704
- Conditions
- Complicated Intra-abdominal Infections; Complicated Appendicitis
- Interventions
- Eravacycline; Meropenem; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-10-13
- Completion
- 2017-05-19
- Enrolment
- 500
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionComplicated Intra-abdominal Infections; Complicated AppendicitisInterventionEravacycline; Meropenem; PlaceboPhasePhase 3Registry statusCompletedThe Effect of Colistin Inhalation on Ventilator Associated Pneumonia
NCT03622450 · start 2016-01-02
Registered record
- Registry ID
- NCT03622450
- Conditions
- Ventilator Associated Pneumonia
- Interventions
- Colistin; Carbapenem + Aminoglycoside/ Quinolone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2016-01-02
- Completion
- 2018-01-10
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVentilator Associated PneumoniaInterventionColistin; Carbapenem + Aminoglycoside/ QuinolonePhasePhase 2 / Phase 3Registry statusCompletedEvaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).
NCT02475733 · start 2015-08-01
Registered record
- Registry ID
- NCT02475733
- Conditions
- Complicated Intra-abdominal Infections
- Interventions
- Ceftazidime -avibactam; Meropenem; Metronidazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-08-01
- Completion
- 2017-06-01
- Enrolment
- 83
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionComplicated Intra-abdominal InfectionsInterventionCeftazidime -avibactam; Meropenem; MetronidazolePhasePhase 2Registry statusCompletedShort Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO
NCT02149329 · start 2014-12
Registered record
- Registry ID
- NCT02149329
- Conditions
- Febrile Neutropenia; Hematological Malignancy
- Interventions
- Discontinuation of imipenem-cilastatin or meropenem
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-12
- Completion
- 2019-08-05
- Enrolment
- 276
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFebrile Neutropenia; Hematological MalignancyInterventionDiscontinuation of imipenem-cilastatin or meropenemPhasePhase 4Registry statusCompletedMeropenem and Ciprofloxacin Dosing in Septic Shock
NCT02240277 · start 2014-11
Registered record
- Registry ID
- NCT02240277
- Conditions
- Septic Shock
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2014-11
- Completion
- 2016-03
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeptic ShockInterventionNot recordedPhaseNot recordedRegistry statusUnknownA Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
NCT01970371 · start 2014-09-16
Registered record
- Registry ID
- NCT01970371
- Conditions
- Bloodstream Infections (BSI) Due to CRE; Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE; Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE; Complicated Urinary Tract Infection (cUTI) Due to CRE; Acute Pyelonephritis (AP) Due to CRE
- Interventions
- plazomicin; colistin; meropenem; tigecycline; antibiotic of Investigator's choice
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-09-16
- Completion
- 2016-09-15
- Enrolment
- 69
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBloodstream Infections (BSI) Due to CRE; Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE; Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE; Complicated Urinary Tract Infection (cUTI) Due to CRE +1 moreInterventionplazomicin; colistin; meropenem; tigecycline +1 morePhasePhase 3Registry statusCompletedSafety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
NCT02070757 · start 2014-09-02
Registered record
- Registry ID
- NCT02070757
- Conditions
- Healthcare-Associated Pneumonia; Ventilator-Associated Pneumonia; Lung Diseases
- Interventions
- Ceftolozane/tazobactam; Meropenem
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-09-02
- Completion
- 2018-06-06
- Enrolment
- 726
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthcare-Associated Pneumonia; Ventilator-Associated Pneumonia; Lung DiseasesInterventionCeftolozane/tazobactam; MeropenemPhasePhase 3Registry statusCompletedPharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis
NCT07113587 · start 2014-04-08
Registered record
- Registry ID
- NCT07113587
- Conditions
- Peritoneal Dialysis-associated Peritonitis; Peritoneal Dialysis (PD); Pharmacokinetics; Intravenous Administration; Intravenous; Meropenem; Intraperitoneal; Ampicillin; Aztreonam; Ciprofloxacin; Minimum Inhibitory Concentration (MIC)
- Interventions
- Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2014-04-08
- Completion
- 2017-07-07
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPeritoneal Dialysis-associated Peritonitis; Peritoneal Dialysis (PD); Pharmacokinetics; Intravenous Administration +7 moreInterventionApplication of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis; Application of intraperitoneal and intravenous ciprofloxacin in automated peritoneal dialysis patients without peritonitisPhasePhase 2 / Phase 3Registry statusCompletedIntermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis
NCT02048163 · start 2013-12
Registered record
- Registry ID
- NCT02048163
- Conditions
- Cystic Fibrosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Withdrawn
- Start
- 2013-12
- Completion
- 2015-08
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCystic FibrosisInterventionNot recordedPhaseNot recordedRegistry statusWithdrawnPharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)
NCT02287493 · start 2013-07
Registered record
- Registry ID
- NCT02287493
- Conditions
- Replacement Therapy, Renal
- Interventions
- Pharmacokinetic Analysis
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2013-07
- Completion
- 2016-12
- Enrolment
- 35
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionReplacement Therapy, RenalInterventionPharmacokinetic AnalysisPhaseNot recordedRegistry statusCompletedMulticenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem
NCT01732250 · start 2013-03
Registered record
- Registry ID
- NCT01732250
- Conditions
- Gram-Negative Bacterial Infections
- Interventions
- Colistin; Meropenem
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2013-03
- Completion
- 2017-02-28
- Enrolment
- 406
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGram-Negative Bacterial InfectionsInterventionColistin; MeropenemPhasePhase 4Registry statusCompletedA Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization
NCT01797133 · start 2013-02
Registered record
- Registry ID
- NCT01797133
- Conditions
- All Hospitalzied Patients; No Specific Conditions Requires
- Interventions
- ID fellow-based antibiotic pre-authorization; Pharmacist-based antibiotic pre-authorization
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2013-02
- Completion
- 2013-12
- Enrolment
- 984
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAll Hospitalzied Patients; No Specific Conditions RequiresInterventionID fellow-based antibiotic pre-authorization; Pharmacist-based antibiotic pre-authorizationPhaseNot applicableRegistry statusCompletedMulti-center Clinical Study of Early Antibios of Severe Acute Pancreatitis
NCT01992198 · start 2012-07
Registered record
- Registry ID
- NCT01992198
- Conditions
- Pancreatitis,Acute Necrotizing
- Interventions
- cefoperazone + metronidazole; oral care by chlorhexidine gluconate; enteral nutrition; Somatostatin; Meropenem
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2012-07
- Completion
- 2016-12
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPancreatitis,Acute NecrotizingInterventioncefoperazone + metronidazole; oral care by chlorhexidine gluconate; enteral nutrition; Somatostatin +1 morePhasePhase 4Registry statusUnknownCompare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections
NCT01499290 · start 2012-03
Registered record
- Registry ID
- NCT01499290
- Conditions
- Complicated Intra-Abdominal Infection
- Interventions
- CAZ-AVI; Metronidazole; Meropenem
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-03
- Completion
- 2014-04
- Enrolment
- 493
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionComplicated Intra-Abdominal InfectionInterventionCAZ-AVI; Metronidazole; MeropenemPhasePhase 3Registry statusCompleted